Table 3.
Sensitivity analysis of the efficacy of drugs targeting different species of schistosome (RCTs only)
| Study | Method* | No. of Trials | Participants (N1/N2) | Pooled RRs (95%CI) | Heterogeneity Test (P ) |
|---|---|---|---|---|---|
| A | 8 | 348/220 | 0.27 (0.22, 0.33) | 0.88 | |
| PZQ (RCTs) for treatment | B | 7 | 232/177 | 0.28 (0.22, 0.35) | 0.90 |
| C | 6 | 336/207 | 0.27 (0.22, 0.32) | 0.70 | |
| D | 5 | 220/164 | 0.28 (0.22, 0.35) | 0.70 | |
| AM for prevention (8-13 doses by 15-day interval) | A | 6 | 2429/2563 | 0.10 (0.05, 0.21) | <0.01 |
| E | 5 | 1996/2111 | 0.12 (0.06, 0.24) | <0.01 | |
| AS (6 mg/kg) 8 doses by 1-week interval for preventing | A | 4 | 813/720 | 0.03 (0.01, 0.12) | 0.89 |
| F | 2 | 572/502 | 0.02 (0.00, 0.14) | 0.73 | |
| AS (6 mg/kg) 8-14 doses by 2-week interval for preventing | A | 5 | 3317/3553 | 0.05 (0.03, 0.09) | 0.93 |
| G | 4 | 879/893 | 0.04 (0.01, 0.14) | 0.83 | |
| AS (6 mg/kg) 3-5 doses by 2-week interval for preventing | A | 4 | 714/768 | 0.29 (0.16, 0.52) | 0.20 |
| H | 3 | 334/368 | 0.39 (0.20, 0.76) | 0.39 |
*A: all trials were included in each subgroup, respectively.
B: one trial [34] with S. japonicum species was excluded.
C: two trials [36] with S. mansoni species were excluded.
D: three trials [34,36] were excluded, the remaining with S. haematoium.
E: one trial [47] in which there was zero person positive in the treatment group was excluded.
F: two trials from the same study [56] were excluded.
G: one trial [53] with the largest sample size was excluded.
H: one trial [52] with the largest sample size was excluded.